The Biliary Atresia Therapeutics Market Size in the 7MM is projected to continue growing significantly at a CAGR of 7.7% by 2034, estimates DelveInsight

DelveInsight's "Biliary Atresia Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding, historical and forecasted epidemiology, as well as the Biliary Atresia market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Discover Key Insights into the Biliary Atresia Market with DelveInsight's In-Depth Report @ Biliary Atresia Market Size- https://www.delveinsight.com/sample-request/biliary-atresia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Biliary Atresia Market Report
• In April 2026, Albireo, an Ipsen Company, conducted a Phase 3 study to investigate the efficacy and safety of odevixibat compared to placebo in children with biliary atresia who have undergone a Kasai hepatoportoenterostomy.
• In March 2026, Mirum Pharmaceuticals Inc. initiated a study is to determine whether the investigational treatment (maralixibat) is safe and effective in pediatric and adult participants who have cholestatic liver disease with pruritus that has been refractory to other therapies, and who have no other treatment options.
• According to DelveInsight's epidemiology model, in 2023, the Incident cases of biliary atresia in the US was found to be approximately 338, these case are expected to increase by 2034.
• In 2023, there were nearly 17 cases of Type I, 7 cases of Type II and 315 cases for Type III. Our estimates suggest that these cases will change during the forecast period (2024-2034).
• In 2023, Germany saw approximately 34 cases of biliary atresia, with around 17 cases in males and 18 in females.
• In 2023, in the UK there were approximately 19 cases of biliary atresia in males and 25 cases in females. Assessments as per DelveInsight's analysts show that the overall cases of biliary atresia in both the genders is subjected to decrease in the coming years directly attributed to the country population that is decreasing by 2034, in males and females, respectively.
• In 2023, in Japan there were 11 cases of Type I and 2 cases of Type II. Assessments as per DelveInsight's analysts show that the overall incidence of biliary atresia is maximum for type III with 80 cases.
• The leading Biliary Atresia Companies such as Mirium Pharmaceuticals, Albireo, Intercept Pharmaceuticals, and others.
• Promising Biliary Atresia Therapies such as BYLVAY, LIVMARLI, and others.

Stay ahead in the Biliary Atresia Therapeutics Market with DelveInsight's Strategic Report @ Biliary Atresia Market Outlook- https://www.delveinsight.com/sample-request/biliary-atresia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Biliary Atresia Epidemiology Segmentation in the 7MM
• Total Biliary Atresia Incident cases
• Biliary Atresia Type-specific cases
• Biliary Atresia Gender-specific cases
• Biliary Atresia Treated cases

Download the report to understand which factors are driving Biliary Atresia epidemiology trends @ Biliary Atresia Prevalence- https://www.delveinsight.com/sample-request/biliary-atresia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Biliary Atresia Emerging Drugs
• BYLVAY (odevixibat): Ipsen
Odevixibat (A-4250), a potent and selective inhibitor of the ileal bile acid transporter (IBAT), also known as apical sodium-dependent bile acid transporter (ASBT), acts locally in the gut, and has minimal systemic exposure at the therapeutic dose. IBAT initiates the transport of bile acids, which flow through the portal vein back to the liver in a process known as enterohepatic circulation. Approximately 95% of bile acids are recirculated via the IBAT to the liver. Accordingly, a product capable of inhibiting the IBAT could lead to a reduction in bile acids returning to the liver and may represent a promising approach for treating cholestatic liver diseases. Odevixibat is being developed by Ipsen that completed acquisition of Albireo, expanding the scope of its rare disease portfolio.

• Obeticholic Acid: Intercept Pharmaceuticals
Obeticholic acid (OCA) is a first-in-class agonist that selectively binds to the farnesoid X receptor (FXR), a nuclear receptor expressed in the liver and intestine. FXR is a key regulator of bile acid, inflammatory, fibrotic, and metabolic pathways. FXR activation decreases the intracellular hepatocyte concentrations of bile acids by suppressing de novo synthesis from cholesterol as well as by increased transport of bile acids out of the hepatocytes. These mechanisms limit the overall size of the circulating bile acid pool while promoting choleresis, thus reducing hepatic exposure to bile acids.

Biliary Atresia Market Outlook
Biliary atresia is characterized by a fibro proliferative obliteration of the biliary tree that progresses toward hepatic fibrosis, cirrhosis, and end-stage liver failure. The treatment of BA is surgical and currently recommended as a sequence of, eventually, two interventions. During the first months of life, a Hepatoportoenterostomy (a "Kasai," modifications) should be performed, to restore the biliary flow to the intestine and lessen further damage to the liver. If this fails or the disease progresses towards biliary cirrhosis and life-threatening complications, then liver transplantation is indicated, for which biliary atresia represents the most frequent pediatric indication.

Get In-Depth Knowledge on Biliary Atresia Market Trends and Forecasts with DelveInsight @ Biliary Atresia Treatment Market- https://www.delveinsight.com/sample-request/biliary-atresia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Biliary Atresia Drugs Market Insights
In the postoperative management, medical care following hepatoportoenterostomy consists of interventions such as choleretics and possible use of anti-inflammatory medications, nutritional rehabilitation, fat-soluble vitamin supplementation, prevention of cholangitis, management of portal hypertension and its sequel. Long-term antibiotic prophylaxis, such as trimethoprim-sulfamethoxazole, is often prescribed to reduce the risk of cholangitis, an infection of the bile ducts that can occur post-surgery. While there is no conclusive evidence supporting its efficacy, it is commonly used in clinical practice. Ursodeoxycholic acid may enhance bile flow in patients with a patent biliary system after the Kasai procedure. It has been shown to improve outcomes in some infants, although its long-term safety profile requires careful monitoring due to potential adverse effects observed in other conditions.

Scope of the Biliary Atresia Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Forecast Period- 2024-2034
• Biliary Atresia Companies- Mirium Pharmaceuticals, Albireo, Intercept Pharmaceuticals, and others.
• Biliary Atresia Therapies- BYLVAY, LIVMARLI, and others.
• Biliary Atresia Market Dynamics: Biliary Atresia Market Drivers and Barriers
• Biliary Atresia Market Access and Reimbursement, Unmet Needs and Future Perspectives

Unlock Strategic Insights with DelveInsight's Comprehensive Biliary Atresia Market Report @ Biliary Atresia Market Drivers and Barriers- https://www.delveinsight.com/sample-request/biliary-atresia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1 Key Insights
2 Report Introduction
3 Market Overview at a Glance
4 Epidemiology and Market Forecast Methodology
5 Executive Summary
6 Key Events
7 Disease Background and Overview
8 Patient Journey
9 Epidemiology and Patient Population
10 Emerging Drugs
11 Biliary atresia: Market Analysis
12 Key Opinion Leaders' Views
13 SWOT Analysis
14 Unmet Needs
15 Market Access and Reimbursement
16 Appendix
17 DelveInsight Capabilities
18 Disclaimer
19 About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.